Madrigal's Rezdiffra showed significant liver stiffness reduction in MASH cirrhosis. The company also beat Q4 earnings and ...

Madrigal Pharmaceuticals (MDGL) reported Q4 results and provided a 2-year update from the open-label metabolic dysfunction-associated ...

Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales ...

Reports Q4 revenue $103.3M, consensus $97.81M. Bill Sibold, Chief Executive Officer of Madrigal, stated, “Looking back on 2024, I’m incredibly ...

The British drugmaker claimed study success in a first-line setting in breast cancer. Elsewhere, Rezdiffra sales continued to ...

They still view Iglesias as “not a fit” for their roster, according to a person familiar with the Mets’ thinking. That leaves ...

New York Mets infielder Nick Madrigal dislocated his non-throwing shoulder Sunday in a spring training game against the ...

WEST CONSHOHOCKEN, Pa. (AP) — WEST CONSHOHOCKEN, Pa. (AP) — Madrigal Pharmaceuticals Inc. (MDGL) on Wednesday reported a loss of $59.4 million in its fourth quarter. The West Conshohocken, ...

The Mets’ bench competition experienced some early upheaval on Sunday, when infielder Nick Madrigal dislocated his left ...

Nick Madrigal dislocated his left shoulder during today’s Spring Training split-squad game between the Mets and Nationals. In ...

In just the second day of Spring Training games, the New York Mets lost a key offseason acquisition, testing their infield ...

Copyright © 2025 Bleacher Report, Inc. A Warner Bros. Discovery Company. All Rights Reserved.